Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739229

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739229

Relapsed or Refractory Diffuse Large B Cell Lympho

PUBLISHED:
PAGES: 294 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Relapsed or Refractory Diffuse Large B Cell Lympho Market to Reach US$1.8 Billion by 2030

The global market for Relapsed or Refractory Diffuse Large B Cell Lympho estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monjuvi, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$456.4 Million by the end of the analysis period. Growth in the XPOVIO segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$408.0 Million While China is Forecast to Grow at 5.3% CAGR

The Relapsed or Refractory Diffuse Large B Cell Lympho market in the U.S. is estimated at US$408.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$343.0 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global “Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)” Market - Key Trends & Drivers Summarized

Why Is Relapsed or Refractory DLBCL a Persistent Challenge in Oncology?

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30% of all NHL cases worldwide. While first-line therapies such as R-CHOP (rituximab with chemotherapy) achieve remission in a significant number of patients, about 30-40% experience relapse or do not respond to initial treatment-classified as relapsed or refractory (R/R) DLBCL. This patient subgroup faces a poor prognosis, with limited curative options. The heterogeneity of the disease, often driven by genetic abnormalities like MYC, BCL2, and BCL6 rearrangements, complicates treatment strategies. Conventional salvage therapies such as high-dose chemotherapy followed by autologous stem cell transplant are often unsuitable due to age or comorbidities, leaving a therapeutic gap. The unmet clinical need in this space is immense, spurring ongoing research and innovation in both targeted and cellular immunotherapies.

How Are Innovative Therapies Transforming the Outlook for R/R DLBCL Patients?

Breakthrough therapies are redefining the standard of care for R/R DLBCL and bringing renewed hope to patients who were previously considered incurable. Among the most impactful innovations are chimeric antigen receptor T-cell (CAR-T) therapies, including axicabtagene ciloleucel and tisagenlecleucel, which have shown substantial complete remission rates even in heavily pre-treated patients. These personalized cell-based therapies reprogram a patient's own immune cells to recognize and kill lymphoma cells. In parallel, antibody-drug conjugates (ADCs) like polatuzumab vedotin and bispecific antibodies such as glofitamab are emerging as viable off-the-shelf options with high efficacy and manageable toxicity profiles. Small molecule inhibitors targeting key pathways such as BTK, PI3K, and BCL2 are also under active investigation. The development of these therapies reflects a broader trend toward precision oncology, where treatments are increasingly tailored to the molecular profile of the patient’s disease, transforming once-fatal relapses into manageable chronic conditions or potential cures.

Which Healthcare and Market Dynamics Are Shaping the Adoption of These Therapies?

The R/R DLBCL treatment market is being shaped by a convergence of regulatory, healthcare system, and payer dynamics. Regulatory bodies such as the FDA and EMA have granted accelerated approvals and breakthrough designations to several advanced therapies, fast-tracking access and incentivizing further R&D. However, high treatment costs, especially for CAR-T therapies, have sparked debate over reimbursement models and accessibility. Payers are increasingly evaluating outcomes-based contracts and value-based care agreements to manage the financial risk of adopting these high-cost therapies. Healthcare providers are also investing in infrastructure and training for administering complex treatments like CAR-T, which require specialized centers and multidisciplinary teams. Meanwhile, pharmaceutical companies are developing next-generation CAR-Ts with reduced manufacturing times and off-the-shelf formats to improve scalability and reduce treatment delays. Patient advocacy groups and digital platforms are also playing a role by increasing awareness, supporting access programs, and connecting patients to clinical trials.

The Growth in the Relapsed or Refractory DLBCL Market Is Driven by Breakthrough Immunotherapies, Precision Oncology Trends, and Infrastructure Expansion for Complex Biologics

The growth in the relapsed or refractory DLBCL market is driven by several interlinked factors. Chief among them is the rise of next-generation immunotherapies-particularly CAR-T cell therapies, ADCs, and bispecific antibodies-which are transforming survival outcomes for patients with limited options. Secondly, the adoption of precision medicine, enabled by genomic profiling and companion diagnostics, is allowing oncologists to identify high-risk DLBCL subsets and match them with targeted therapies. Thirdly, improvements in biopharmaceutical manufacturing, including automation and decentralized CAR-T production models, are enhancing the accessibility and scalability of advanced treatments. Fourthly, growing investments by hospitals and oncology centers in cell therapy units and specialized infusion facilities are making it easier to deliver complex biologics safely and efficiently. Additionally, supportive healthcare policies, fast-track approvals, and expanded clinical trial networks are helping bring innovative therapies to market faster. Lastly, patient demand for more durable and less toxic alternatives to traditional chemotherapy is pushing physicians and payers to adopt these novel therapies as part of an evolving standard of care.

SCOPE OF STUDY:

The report analyzes the Relapsed or Refractory Diffuse Large B Cell Lympho market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Other Drug Types); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Adaptive Biotechnologies Corp.
  • ADC Therapeutics SA
  • Bristol Myers Squibb
  • Cellular Biomedicine Group Inc.
  • Eagle Pharmaceuticals, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hoffmann-La Roche AG
  • IMV Inc.
  • Incyte Corporation
  • Janssen Biotech, Inc.
  • Karyopharm Therapeutics
  • Merck & Co., Inc.
  • MorphoSys U.S. Inc.
  • Novartis AG
  • Overland Pharmaceuticals
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34285

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Relapsed or Refractory Diffuse Large B Cell Lympho - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Non-Hodgkin Lymphoma Drives Demand for Second-Line Treatment Options
    • Breakthrough Approvals in CAR-T Cell Therapy Expand Advanced Treatment Availability
    • Pipeline Development of Bispecific Antibodies Spurs Competitive Innovation
    • Shift Toward Personalized Oncology Enhances Role of Genomic Profiling in R/R DLBCL Treatment
    • Increased Clinical Trial Activity Across Immunotherapy Classes Expands Market Opportunities
    • Regulatory Fast Track Designations Accelerate Access to Novel Drug Classes
    • Adoption of Antibody-Drug Conjugates (ADCs) Strengthens Outcomes in Refractory Patients
    • Growing Hospital Investment in Cell Therapy Infrastructure Supports CAR-T Commercialization
    • Rise in Patient Assistance Programs Enhances Access to High-Cost Treatment Modalities
    • Use of Companion Diagnostics Improves Patient Stratification and Therapeutic Precision
    • Strategic Pharma Collaborations Fuel Co-Development of Targeted Agents
    • Expansion of Academic Research into Resistance Mechanisms Spurs Innovation
    • Shift from Chemotherapy-Dependent Approaches to Immuno-Oncology Alters Treatment Landscape
    • Global Expansion of Cell Therapy Manufacturing Capacity Increases Access in Emerging Markets
    • Increasing Physician Familiarity with Multi-Line Treatment Protocols Improves Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Relapsed or Refractory Diffuse Large B Cell Lympho Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monjuvi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for XPOVIO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Polivy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Kymriah by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Yescarta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!